Shares of Wave Life Sciences Ltd. (WVE) tanked over 55% on Thursday even after the company reported encouraging early-stage clinical data.
The stock is currently trading at $5.53, down $6.78 or 55.08%, on the Nasdaq. It opened at $5.36 after closing the previous session at $12.30. The stock has traded between $5.02 and $21.73 over the past 52 weeks.
Wave Life Sciences announced positive interim results from its Phase 1 INLIGHT trial of WVE-007, showing meaningful improvements in body composition after a single dose.
At six months, the treatment delivered a 14% reduction in visceral fat, along with reductions in total fat, waist circumference, and body weight, while preserving lean muscle mass.
The therapy also demonstrated durable, dose-dependent activity and was reported to be safe and well tolerated.
Despite the positive data, the steep decline in shares suggests investor concerns around the early-stage nature of the trial, future development risks, or expectations already being priced in ahead of the results.
The company said it remains on track to begin the Phase 2a portion of the INLIGHT study in the second quarter of 2026, targeting patients with higher BMI and related comorbidities.
For comments and feedback contact: editorial@rttnews.com
Business News
May 15, 2026 15:25 ET Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.